Recursive Language Models aim to break the usual trade off between context length, accuracy and cost in large language models. Instead of forcing a model to read a giant prompt in one pass, RLMs treat ...
Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...
Advanced data visualization and analytics have become central to enterprise IT strategies as organizations face rapid data growth from cloud services, software-as-a-service applications, edge devices, ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Is your feature request related to a problem or challenge? Currently, AlgoVisualizer does not include any visualization for constraint-based problems like Sudoku. This makes it difficult for learners ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
When Nick Watkins was a child, he pasted articles about space exploration into scrapbooks and drew annotated diagrams of rockets. He knew this because, years later, he still had the scrapbooks, and ...
Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback